Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients

Argent, Elizabeth; Kainer, Gad; Aitken, Maggie; Rosenberg, Andrew R.; Mackie, Fiona

doi:10.1034/j.1399-3046.2003.02048.x

Cited by 28 publications

(15 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only limited data are available regarding the safe use of statins in pediatric renal patients, including transplant recipients, and any published studies so far have only included lowdose statins. For example, Argent et al [22] studied a cohort of 18 renal transplant patients prescribed a low-dose atorvastatin (5 mg for patients weighing \50, 10 mg for those weighing [50 kg). Another complicating factor for patients with renal disease is the potential for compromised glomerular filtration rates.…”

Section: Discussionmentioning

confidence: 99%

Statin Use in Australian Children: A Retrospective Audit of Four Pediatric Hospitals

et al. 2014

View full text Add to dashboard Cite

Statins were prescribed to children younger than suggested by current Australian guidelines, with atorvastatin being the preferred statin of choice. Long-term safety studies on the use of statins in children have only included FH patients so far, who are generally healthy besides their raised lipid levels. Further long-term safety studies are needed to include the more vulnerable transplant and renal patients, identified in this audit as being prescribed statins. This can help formulate guidelines for the safest possible use of this class of drugs in the pediatric setting, including the possibility of weight-based recommendations for younger children.

show abstract

Section: Discussionmentioning

confidence: 99%

Statin Use in Australian Children: A Retrospective Audit of Four Pediatric Hospitals

et al. 2014

View full text Add to dashboard Cite

show abstract

“…[76] The use of HMG-CoA reductase inhibitors (statins), particularly pravastatin and atorvastatin, has been shown to be safe and effective in pediatric kidney and heart transplant recipients. [80][81][82] …”

Section: Dyslipidemiamentioning

confidence: 98%

Adverse Effects of Immunosuppression in Pediatric Solid Organ Transplantation

2010

View full text Add to dashboard Cite

Solid organ transplantation is a life-saving treatment for end-stage organ failure in children. Immunosuppressant medications are used to prevent rejection of the organ transplant. However, these medications are associated with significant adverse effects that impact growth and development, quality of life (QOL), and sometimes long-term survival after transplantation. Adverse effects can differ between the immunosuppressants, but many result from the overall state of immunosuppression. Strategies to manage immunosuppressant adverse effects often involve minimizing exposure to the drugs while balancing the risk for rejection. Early recognition of immunosuppressant adverse effects may help to reduce morbidities associated with solid organ transplantation, improve QOL, and possibly increase overall patient survival.

show abstract

“…Atorvastatin (in low doses, 2.5 mg to 10 mg/day) produced a reduction in TC levels by 32%-41%, in LDL-C levels by 42%-57%, while one study showed a decrease in apo B concentration by 29.5% and the other in TG levels by 44% [209,210]. No adverse events were reported in any study.…”

Section: Statins In Paediatric and Adolescent Transplant Recipientsmentioning

confidence: 72%

“…Two statins that have been evaluated in renal transplant patients are atorvastatin and pravastatin [208][209][210][211]. Atorvastatin (in low doses, 2.5 mg to 10 mg/day) produced a reduction in TC levels by 32%-41%, in LDL-C levels by 42%-57%, while one study showed a decrease in apo B concentration by 29.5% and the other in TG levels by 44% [209,210].…”

Section: Statins In Paediatric and Adolescent Transplant Recipientsmentioning

confidence: 98%

Statins and Solid Organ Transplantation

Gazi¹,

Liberopoulos²,

Athyros³

et al. 2006

CPD

View full text Add to dashboard Cite

Dyslipidaemia is common in solid organ transplant recipients and its presence is associated with chronic rejection and accelerated atherosclerosis, leading to an increased prevalence of cardiovascular disease (CVD). CVD is a major cause of morbidity and mortality in transplant recipients. It is therefore of interest and clinical value to introduce agents that effectively and safely reduce the incidence of this outcome. In the present review we consider the potential benefits of statin administration in adults who have undergone solid organ (mainly renal, heart and liver) transplantation, as well as in paediatric transplant patients. We also briefly review the effects of combination therapy with ezetimibe and statins in this population. Overall, statins are efficient and safe drugs for the management of dyslipidaemias in transplant populations, and in most trials they had a beneficial effect on long-term survival rates, CVD events and rejection rates. The transplanted population is different from other patient groups, mostly due to concomitant immunosuppressive therapy. Statins, at an appropriate dosage, should be prescribed to dyslipidaemic transplanted patients but they should be closely monitored for adverse effects.

show abstract

Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients

Cited by 28 publications

References 27 publications

Statin Use in Australian Children: A Retrospective Audit of Four Pediatric Hospitals

Statin Use in Australian Children: A Retrospective Audit of Four Pediatric Hospitals

Adverse Effects of Immunosuppression in Pediatric Solid Organ Transplantation

Statins and Solid Organ Transplantation

Contact Info

Product

Resources

About